1972 Central Research Institute established in the Tokyo office.
1987 American Peptide Company established in Silicon Valley, CA, U.S.A.
1990 Central Research Institute moved to Moriya city, Ibaraki pref., Japan.
1991 “Hemron”, an iron-supply food ingredient, heme iron marketed.
1992 “Thrombin”, a drug substance, manufacturing license acquitted.
c-GMP facility for pharmaceutical peptide production built.
1994 ELCATONIN “ITO”, a drug substance, approved.
1995 “Liver-Hi”, a liver-hydrolysate, food ingredient marketed.
1996 “GLUCAGON FOR INJECTION '' ITO '' ”, a glucagon formulation, approved.
1999 “ITORELIN”, buserelin acetate formulation, approved.
2000 Health Science Division established in Itoham Foods.
2002 c-GMP plant of American Peptide Company built in Vista, CA, U.S.A.
“MINIHEPA INJECTION 500”, a parnaparin sodium formulation, approved.
2003 Ito Life Sciences, Inc. established.
“VETERINARY ITORELIN INJECTION”, a busererin acetate formulation, approved.
“L-Carnitine”, “L-Carnitine Fumarate” , food ingredients, marketed.
2004 “RESOLMIN INJECTION 1000”, a dalteparin sodium formulation, approved.
2008 All the shares of Ito Life Sciences, Inc. including American Peptide Company and Ito Life Sciences (Shanghai) transferred to Otsuka Chemical Co.,Ltd.
2009 The company name changed to ILS Inc.
2011 “L-Carnitine L-Tartrate”, food ingredient, marketed.
2014 “Hemron 2HiWS”, a concentrated, water-soluble heme iron marketed.
2015 “L-Carnitine A”, “L-Carnitine Fumarate A” and “L-Carnitine L-Tartrate A” made-in-Japan food ingredients, marketed.
All the shares of American Peptide Company transferred to Bachem Holding AG.
DESMOPRESSIN NASAL SPRAY 0.01% “ILS”, a desmopressin formulation , approved.
Exclusive Agency agreement in Japan with Bachem Holding AG, concluded.

go to page top